Analysts move to the sidelines on CoreWeave stock after big surge since IPO

CoreWeave, an AI cloud computing stock, is facing increased caution from Wall Street analysts, with Mizuho and Stifel downgrading it to 'hold' and Citigroup issuing a downside catalyst watch. This shift in sentiment follows the stock's recent 266%+ surge and its $9 billion all-stock acquisition of Core Scientific. Analysts cite the stock's rapid appreciation, a rebalancing risk-to-reward profile, high customer concentration, and the acquisition's impact on valuation structure as reasons for their tempered outlook, suggesting potential near-term downside despite the strategic move.

Analysis

Wall Street sentiment on CoreWeave is turning markedly cautious following a more than 266% stock surge over the past three months. This shift is evidenced by recent downgrades to 'hold' from both Mizuho Securities and Stifel, alongside a 'downside catalyst watch' from Citigroup. The primary drivers for this tempered outlook are valuation concerns and the implications of its planned $9 billion all-stock acquisition of Core Scientific. Stifel's price target of $115 implies a potential 28% downside, arguing that the acquisition repositions CoreWeave as a vertical data center provider, which alters its valuation structure and makes the current share price appear 'fairly valued'. Mizuho, with a $150 price target, points to a rebalancing risk-to-reward skew after the stock's outsized run, while also flagging fundamental risks such as 'very high customer concentration' and an 'unclear' competitive position in inference workloads. Adding to near-term headwinds, Citigroup notes a potential arbitrage opportunity, suggesting investors may sell CoreWeave to buy the target company, Core Scientific, at a significant discount to the acquisition price, creating downward pressure.

Key Decisions for Investors

• Given the recent downgrades and price targets suggesting limited upside or potential downside, investors with significant gains from the stock's 266% run-up should consider trimming positions to de-risk and lock in profits.
• Potential new investors should exercise caution, as the acquisition of Core Scientific introduces significant integration risk and fundamentally changes the company's valuation profile, suggesting the recent powerful momentum may cool off.
• Monitor key catalysts closely, including the progress of the Core Scientific integration, any announcements regarding customer diversification to mitigate concentration risk, and the share price of Core Scientific (CORZ) for signs of the arbitrage pressure highlighted by Citigroup.